NO124600B - - Google Patents
Download PDFInfo
- Publication number
- NO124600B NO124600B NO3956/69A NO395669A NO124600B NO 124600 B NO124600 B NO 124600B NO 3956/69 A NO3956/69 A NO 3956/69A NO 395669 A NO395669 A NO 395669A NO 124600 B NO124600 B NO 124600B
- Authority
- NO
- Norway
- Prior art keywords
- pyridyl
- compound
- prepared
- hydroxyphenyl
- isonicotinoyl
- Prior art date
Links
- 238000000034 method Methods 0.000 claims description 15
- -1 hydroxy, methyl Chemical group 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- FMDGBNOKORNXFS-UHFFFAOYSA-N (2-propan-2-yl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CC(C)C=1OC2=CC=CC=C2C=1C(=O)C1=CC=NC=C1 FMDGBNOKORNXFS-UHFFFAOYSA-N 0.000 claims description 5
- 150000003217 pyrazoles Chemical class 0.000 claims description 5
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 4
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- MFOAZWWJQXMCGY-UHFFFAOYSA-N bis(1-benzofuran-3-yl)methanone Chemical compound C1=CC=C2C(C(C=3C4=CC=CC=C4OC=3)=O)=COC2=C1 MFOAZWWJQXMCGY-UHFFFAOYSA-N 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Chemical group 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical group COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 50
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 22
- 241000700605 Viruses Species 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 241000709661 Enterovirus Species 0.000 description 11
- FEAWBEXORWNEBV-UHFFFAOYSA-N 2-(5-ethyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CCC=1NN=C(C=2C=CN=CC=2)C=1C1=CC=CC=C1O FEAWBEXORWNEBV-UHFFFAOYSA-N 0.000 description 10
- 239000012895 dilution Substances 0.000 description 10
- 238000010790 dilution Methods 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 235000013601 eggs Nutrition 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- XPFPMBGGYRSASS-UHFFFAOYSA-N (2-butyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=NC=C1 XPFPMBGGYRSASS-UHFFFAOYSA-N 0.000 description 5
- PTAKNRJSEKAGBP-UHFFFAOYSA-N (2-ethyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=NC=C1 PTAKNRJSEKAGBP-UHFFFAOYSA-N 0.000 description 5
- DYIVYCPEISTLRG-UHFFFAOYSA-N 2-(3-ethyl-1-methyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCC1=NN(C)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O DYIVYCPEISTLRG-UHFFFAOYSA-N 0.000 description 5
- 229940126062 Compound A Drugs 0.000 description 5
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000712461 unidentified influenza virus Species 0.000 description 5
- MVHXBACVHWNPDE-UHFFFAOYSA-N (2-methyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CC=1OC2=CC=CC=C2C=1C(=O)C1=CC=NC=C1 MVHXBACVHWNPDE-UHFFFAOYSA-N 0.000 description 4
- OCWNCBPLBLLYDT-UHFFFAOYSA-N 2-(5-propan-2-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CC(C)C=1NN=C(C=2C=CN=CC=2)C=1C1=CC=CC=C1O OCWNCBPLBLLYDT-UHFFFAOYSA-N 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 4
- KJAQRHMKLVGSCG-UHFFFAOYSA-N propan-2-ylhydrazine Chemical compound CC(C)NN KJAQRHMKLVGSCG-UHFFFAOYSA-N 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- HYHWRZLPFDSXAU-UHFFFAOYSA-N 4-methoxy-2-(5-methyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound COC1=CC=C(O)C(C=2C(=NNC=2C)C=2C=CN=CC=2)=C1 HYHWRZLPFDSXAU-UHFFFAOYSA-N 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- XKLVLDXNZDIDKQ-UHFFFAOYSA-N butylhydrazine Chemical compound CCCCNN XKLVLDXNZDIDKQ-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 210000005084 renal tissue Anatomy 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000035931 haemagglutination Effects 0.000 description 2
- 206010023332 keratitis Diseases 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- WHIMZWTZGMGBRW-UHFFFAOYSA-N (2-ethyl-5-methyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CCC=1OC2=CC=C(C)C=C2C=1C(=O)C1=CC=NC=C1 WHIMZWTZGMGBRW-UHFFFAOYSA-N 0.000 description 1
- LUKWGNUVKFXOIC-UHFFFAOYSA-N (2-propyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=NC=C1 LUKWGNUVKFXOIC-UHFFFAOYSA-N 0.000 description 1
- PSAZRCUOVITLAG-UHFFFAOYSA-N (5-bromo-2-ethyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CCC=1OC2=CC=C(Br)C=C2C=1C(=O)C1=CC=NC=C1 PSAZRCUOVITLAG-UHFFFAOYSA-N 0.000 description 1
- AKXOKNCGPBQLCG-UHFFFAOYSA-N (5-chloro-2-ethyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound CCC=1OC2=CC=C(Cl)C=C2C=1C(=O)C1=CC=NC=C1 AKXOKNCGPBQLCG-UHFFFAOYSA-N 0.000 description 1
- INFMMIHAIGZCKS-UHFFFAOYSA-N (5-methoxy-2-methyl-1-benzofuran-3-yl)-pyridin-4-ylmethanone Chemical compound C12=CC(OC)=CC=C2OC(C)=C1C(=O)C1=CC=NC=C1 INFMMIHAIGZCKS-UHFFFAOYSA-N 0.000 description 1
- SHOQNGNCKXPZGH-UHFFFAOYSA-N 1-benzofuran-3-yl(pyridin-4-yl)methanone Chemical compound C=1OC2=CC=CC=C2C=1C(=O)C1=CC=NC=C1 SHOQNGNCKXPZGH-UHFFFAOYSA-N 0.000 description 1
- NEFSEMZHKBUTIB-UHFFFAOYSA-N 2-(1,3-diethyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCC1=NN(CC)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O NEFSEMZHKBUTIB-UHFFFAOYSA-N 0.000 description 1
- KGIRNTGMGIXVAU-UHFFFAOYSA-N 2-(1,3-dimethyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CC1=NN(C)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O KGIRNTGMGIXVAU-UHFFFAOYSA-N 0.000 description 1
- ZFTLDFOVDXCCSA-UHFFFAOYSA-N 2-(1-butyl-3-ethyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCCCN1N=C(CC)C(C=2C(=CC=CC=2)O)=C1C1=CC=NC=C1 ZFTLDFOVDXCCSA-UHFFFAOYSA-N 0.000 description 1
- HVKMTODQBOIBMD-UHFFFAOYSA-N 2-(1-butyl-3-propan-2-yl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCCCN1N=C(C(C)C)C(C=2C(=CC=CC=2)O)=C1C1=CC=NC=C1 HVKMTODQBOIBMD-UHFFFAOYSA-N 0.000 description 1
- PNEPIGKWZUFCLB-UHFFFAOYSA-N 2-(1-ethyl-3-methyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCN1N=C(C)C(C=2C(=CC=CC=2)O)=C1C1=CC=NC=C1 PNEPIGKWZUFCLB-UHFFFAOYSA-N 0.000 description 1
- CISPPGBBAMENMH-UHFFFAOYSA-N 2-(3-butyl-1-ethyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCCCC1=NN(CC)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O CISPPGBBAMENMH-UHFFFAOYSA-N 0.000 description 1
- ZAKHXMKPKBMWEW-UHFFFAOYSA-N 2-(3-butyl-1-methyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCCCC1=NN(C)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O ZAKHXMKPKBMWEW-UHFFFAOYSA-N 0.000 description 1
- LWJFLZFOXVFSHD-UHFFFAOYSA-N 2-(3-butyl-1-propan-2-yl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCCCC1=NN(C(C)C)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O LWJFLZFOXVFSHD-UHFFFAOYSA-N 0.000 description 1
- GFNCZMXXAXDLNB-UHFFFAOYSA-N 2-(3-ethyl-1-propan-2-yl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCC1=NN(C(C)C)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O GFNCZMXXAXDLNB-UHFFFAOYSA-N 0.000 description 1
- UOGLXWJCDYDKLA-UHFFFAOYSA-N 2-(3-ethyl-1-propyl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CCCN1N=C(CC)C(C=2C(=CC=CC=2)O)=C1C1=CC=NC=C1 UOGLXWJCDYDKLA-UHFFFAOYSA-N 0.000 description 1
- LDMMBSBOVYZKFB-UHFFFAOYSA-N 2-(3-methyl-1-propan-2-yl-5-pyridin-4-ylpyrazol-4-yl)phenol Chemical compound CC(C)N1N=C(C)C(C=2C(=CC=CC=2)O)=C1C1=CC=NC=C1 LDMMBSBOVYZKFB-UHFFFAOYSA-N 0.000 description 1
- LCRFIIFVHGZPHC-UHFFFAOYSA-N 2-(5-butyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CCCCC=1NN=C(C=2C=CN=CC=2)C=1C1=CC=CC=C1O LCRFIIFVHGZPHC-UHFFFAOYSA-N 0.000 description 1
- KZPRJNHBNJTPNO-UHFFFAOYSA-N 2-(5-ethyl-3-pyridin-4-yl-1H-pyrazol-4-yl)-4-methylphenol Chemical compound CCC=1NN=C(C=2C=CN=CC=2)C=1C1=CC(C)=CC=C1O KZPRJNHBNJTPNO-UHFFFAOYSA-N 0.000 description 1
- FIXVVFJQLXMFCT-UHFFFAOYSA-N 2-(5-methyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CC=1NN=C(C=2C=CN=CC=2)C=1C1=CC=CC=C1O FIXVVFJQLXMFCT-UHFFFAOYSA-N 0.000 description 1
- HXXWGVSPETWGDE-UHFFFAOYSA-N 2-(5-propyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CCCC=1NN=C(C=2C=CN=CC=2)C=1C1=CC=CC=C1O HXXWGVSPETWGDE-UHFFFAOYSA-N 0.000 description 1
- OKOXZGVCTGVUCK-UHFFFAOYSA-N 2-(5-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound OC1=CC=CC=C1C1=CNN=C1C1=CC=NC=C1 OKOXZGVCTGVUCK-UHFFFAOYSA-N 0.000 description 1
- OTVPSYVTWJJRCE-UHFFFAOYSA-N 2-[1,3-di(propan-2-yl)-5-pyridin-4-ylpyrazol-4-yl]phenol Chemical compound CC(C)C1=NN(C(C)C)C(C=2C=CN=CC=2)=C1C1=CC=CC=C1O OTVPSYVTWJJRCE-UHFFFAOYSA-N 0.000 description 1
- OZTVSCCOSAASBJ-UHFFFAOYSA-N 4-bromo-2-(5-ethyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CCC=1NN=C(C=2C=CN=CC=2)C=1C1=CC(Br)=CC=C1O OZTVSCCOSAASBJ-UHFFFAOYSA-N 0.000 description 1
- UUVZXPYBDRQFHU-UHFFFAOYSA-N 4-chloro-2-(5-ethyl-3-pyridin-4-yl-1H-pyrazol-4-yl)phenol Chemical compound CCC=1NN=C(C=2C=CN=CC=2)C=1C1=CC(Cl)=CC=C1O UUVZXPYBDRQFHU-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- UKPBXIFLSVLDPA-UHFFFAOYSA-N propylhydrazine Chemical compound CCCNN UKPBXIFLSVLDPA-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 1
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB47297/68A GB1245283A (en) | 1968-10-04 | 1968-10-04 | Pyrazole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO124600B true NO124600B (enrdf_load_stackoverflow) | 1972-05-08 |
Family
ID=10444445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO3956/69A NO124600B (enrdf_load_stackoverflow) | 1968-10-04 | 1969-10-03 |
Country Status (8)
| Country | Link |
|---|---|
| AT (1) | AT286981B (enrdf_load_stackoverflow) |
| BR (1) | BR6912660D0 (enrdf_load_stackoverflow) |
| DK (1) | DK119769B (enrdf_load_stackoverflow) |
| ES (1) | ES372202A1 (enrdf_load_stackoverflow) |
| NL (1) | NL161451C (enrdf_load_stackoverflow) |
| NO (1) | NO124600B (enrdf_load_stackoverflow) |
| SE (1) | SE349032B (enrdf_load_stackoverflow) |
| YU (1) | YU33195B (enrdf_load_stackoverflow) |
-
0
- NL NL6914957.A patent/NL161451C/xx active
-
1969
- 1969-09-24 BR BR212660/69A patent/BR6912660D0/pt unknown
- 1969-10-01 SE SE13538/69A patent/SE349032B/xx unknown
- 1969-10-03 YU YU2486/69A patent/YU33195B/xx unknown
- 1969-10-03 DK DK527569AA patent/DK119769B/da unknown
- 1969-10-03 NO NO3956/69A patent/NO124600B/no unknown
- 1969-10-04 ES ES372202A patent/ES372202A1/es not_active Expired
- 1969-10-06 AT AT941069A patent/AT286981B/de active
Also Published As
| Publication number | Publication date |
|---|---|
| YU33195B (en) | 1976-06-30 |
| DK119769B (da) | 1971-02-22 |
| BR6912660D0 (pt) | 1973-04-19 |
| AT286981B (de) | 1971-01-11 |
| SE349032B (enrdf_load_stackoverflow) | 1972-09-18 |
| NL161451C (nl) | |
| YU248669A (en) | 1975-12-31 |
| ES372202A1 (es) | 1971-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4339445A (en) | Method for combating virus infection | |
| DK169657B1 (da) | Anvendelse af visse uracilnucleosider til fremstilling af et lægemiddel mod adenovirusinfektioner samt oftalmiske præparater indeholdende sådanne uracilnucleosider | |
| PL115117B1 (en) | Method of manufacture of novel carbonyl substituted 1-sulfonylobenzimidazoles | |
| US4990537A (en) | Anti influenza agent | |
| CN105622596B (zh) | 含有烷氧亚胺基氮杂环片段的苯并噻嗪-4-酮类化合物及其制备方法 | |
| US4000281A (en) | Pyrazole derivatives | |
| US20060019927A1 (en) | Anti-viral uses of borinic acid complexes | |
| CN109503510B (zh) | 一种防龋抗菌的噻唑类化合物及其制备方法 | |
| US4340760A (en) | Monophenylamine derivatives | |
| CN105669664A (zh) | 含有碱性氮杂环片段的苯并噻嗪-4-酮类化合物及其制备方法 | |
| NO124600B (enrdf_load_stackoverflow) | ||
| Ruprecht et al. | Castanospermine vs. its 6-O-butanoyl analog: a comparison of toxicity and antiviral activity in vitro and in vivo | |
| FR2493702A1 (fr) | Compositions antivirales contenant des derives d'acide aminosulfonylhalogenobenzoique | |
| US4324916A (en) | Decaprenylamine derivatives | |
| US4755601A (en) | Nonyl prenyl-N heterocyclics | |
| US4322555A (en) | Nonaprenylamine derivatives | |
| US4265910A (en) | Isoprenylamines | |
| JPS5883620A (ja) | 薬剤としての４−フエニル−４−オキソ−２−ブテン酸のある種の誘導体及びそれを含有する組成物 | |
| JPS63170366A (ja) | イミダゾール誘導体、その製造方法及びこれを含有する抗菌剤 | |
| SU1616519A3 (ru) | Способ получени 1,3,4-тиадиазол-2-цианамида или его фармацевтически приемлемых солей | |
| NO174887B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive aryl- alkyl-pyrrol-2-carboxylsyreforbindelser | |
| US5475028A (en) | 2-aminoethanesulfonic acid zinc complex | |
| CN108440446A (zh) | 含有肟基片段的苯并噻嗪-4-酮类化合物及其制备方法 | |
| NO179614B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive 2-formylbenzylfosfonsyre-derivater | |
| US4380668A (en) | Decaprenylamine derivatives |